ID   SC263 R10.2
AC   CVCL_LI56
DR   cancercelllines; CVCL_LI56
DR   Wikidata; Q54952247
RX   PubMed=26269754;
CC   Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; c.704_735del32; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (from parent cell line).
DI   NCIt; C34447; Head and neck squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_LI51 ! NKI-SC263
CA   Cancer cell line
DT   Created: 15-11-17; Last updated: 19-12-24; Version: 9
//
RX   PubMed=26269754; PMCID=PMC4529614;
RA   Boeckx C., Blockx L., Op de Beeck K., Limame R., Van Camp G.,
RA   Peeters M., Vermorken J.B., Specenier P., Wouters A., Baay M.,
RA   Lardon F.;
RT   "Establishment and characterization of cetuximab resistant head and
RT   neck squamous cell carcinoma cell lines: focus on the contribution of
RT   the AP-1 transcription factor.";
RL   Am. J. Cancer Res. 5:1921-1938(2015).
//